. 2017 May 18;102(1):31–40. doi: 10.1189/jlb.4RI1216-516R

Table 1.

CD47‐SIRPα clinical trial data

Compound	Company	Target	Treated disease	Start date	Estimated completion date	Phase
Hu5F9‐G4	Forty Seven Inc., Menlo Park, CA, USA	CD47	Colorectal neoplasms/solid tumors	November 1, 2016	March 1, 2023	Phase I/phase II (cetuximab)
Hu5F9‐G4	Forty Seven Inc.	CD47	Non‐Hodgkin/large B cell lymphoma	November 1, 2016	January 1, 2023	Phase I/phase II (rituximab)
TTI‐621	Trillium Therapeutics Inc., Mississauga, ON, Canada	CD47	Melanoma/breast carcinoma/solid tumors	September 1, 2016	December 1, 2019	Phase I
CC‐90002	Celgene, Summit, NJ, USA	CD47	Acute myeloid leukemia	July 27, 2016	July 1, 2019	Phase I
SIRPα Ab	Nantes University Hospital, Nantes, France	SIRPα	Hepatocellular carcinoma	June 16, 2016	May 1, 2019	Investigation
Hu5F9‐G4	Forty Seven Inc.	CD47	Acute myeloid leukemia	January 27, 2016	January 1, 2018	Phase I
TTI‐621	Trillium Therapeutics Inc.	CD47	Hematologic malignancies	January 19, 2016	June 1, 2019	Phase I
CC‐90002	Celgene	CD47	Hematologic cancers/solid tumors	February 13, 2015	January 1, 2018	Phase I
Hu5F9‐G4	Forty Seven Inc.	CD47	Solid tumors	August 12, 2014	August 1, 2017	Phase I
None	Medical University South Carolina, Charleston, SC, USA	CD47	Multiple myeloma	July 13, 2011	July 1, 2014	Prognostic potential for chemotherapy

Chronological order of anti‐CD47 antibody clinical trials on a variety of human cancers. Most of these trials were started in 2016 and include phase II studies in combination with an additional opsonizing antibody. Data adapted from references 63, 64, 65, 66, 67, 68, 69, 70, 71–72.